Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 6/20 | 0.58 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.58 |
| ▸ | IKBKB | O14920 | 3/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15063693 | 0.86 | KDR (0.61) | KDRPDGFRBTP53MEN1NPC1 | |
| SCHEMBL14697805 | 0.83 | KDR (0.58) | KDRPDGFRBIKBKBMAP4K4GRM1 | |
| SCHEMBL15069721 | 0.83 | KDR (0.64) | KDRPDGFRBIKBKBMEN1KMT2A | |
| SCHEMBL15063946 | 0.78 | KDR (0.53) | KDRPDGFRBCASP1MEN1LMNA | |
| SCHEMBL15063859 | 0.74 | KDR (0.70) | KDRPDGFRBIKBKBMAP4K4PIM1 | |
| SCHEMBL15064055 | 0.74 | KDR (1.00) | KDRPDGFRBMAP4K4MEN1NPC1 | |
| SCHEMBL1837836 | 0.74 | GRM5 (0.45) | KDRPDGFRBIKBKBADORA3ADORA2A | |
| SCHEMBL2339243 | 0.73 | KDM4E (0.45) | GRM5GRM1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10707090 | 0.73 | NPSR1 (0.43) | ADORA3ADORA2AADORA2BADORA1MEN1 | |
| SCHEMBL14413497 | 0.73 | ADORA2A (0.47) | IKBKBADORA2AADORA1MAP4K4CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12162890-B2 | Heteroaromatic NMDA receptor modulators and uses thereof | NOVARTIS AG (CH) | 2024-12-10 | — | — | US | disclosed |
| US-20230023543-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2023-01-26 | — | — | US | disclosed |
| US-11236104-B2 | Heteroaromatic NMDA receptor modulators and uses thereof | CADENT THERAPEUTICS, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210107916-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2021-04-15 | — | — | US | disclosed |
| EP-3386591-B1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | CADENT THERAPEUTICS INC (US) | 2020-06-24 | — | — | EP | disclosed |
| US-10626122-B2 | Heteroaromatic NMDA receptor modulators and uses thereof | CADENT THERAPEUTICS, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| US-20180362541-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2018-12-20 | — | — | US | disclosed |
| EP-3386591-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | Cadent Therapeutics, Inc. (US) | 2018-10-17 | — | — | EP | disclosed |
| WO-2017100591-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | LUC THERAPEUTICS (US) | 2017-06-15 | — | — | WO | disclosed |
| WO-2017100591-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | LUC THERAPEUTICS (US) | 2017-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236104-B2 | Heteroaromatic NMDA receptor modulators and uses thereof | GRIN2C, GRIN2A, GRIN1 | KDR 2832/4885PDGFRB 3052/4885IKBKB 1284/4885 |
| US-10626122-B2 | Heteroaromatic NMDA receptor modulators and uses thereof | GRIN2C, GRIN2A, GRIN1 | KDR 2832/4885PDGFRB 3052/4885IKBKB 1284/4885 |
| US-12162890-B2 | Heteroaromatic NMDA receptor modulators and uses thereof | GRIN2C, GRIN2A, GRIN1 | KDR 2832/4885PDGFRB 3052/4885IKBKB 1284/4885 |
| US-20180362541-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN2C, GRIN2A, GRIN1 | KDR 2832/4885PDGFRB 3052/4885IKBKB 1284/4885 |
| US-20230023543-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN2C, GRIN2A, GRIN1 | KDR 2832/4885PDGFRB 3052/4885IKBKB 1284/4885 |
| US-20210107916-A1 | HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN2C, GRIN2A, GRIN1 | KDR 2832/4885PDGFRB 3052/4885IKBKB 1284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.